Year: 2019
Type: article
Abstract: Chimeric antigen receptor T cell (CART) products have demonstrated promise as a treatment for relapsed or refractory pediatric acute lymphocytic leukemia (ALL) and adult relapsed or refractory diffuse large B cell lymphoma (DLBCL). Logistical complexities, requisite release testing, and other considerations currently favor a centralized manufacturing approach where the apheresis product is shipped fresh or frozen to a centralized manufacturing site and the final product is manufactured and cryopreserved, shipped frozen to the infusing center, and then infused.
Source: Molecular Therapy
Author: Patrick J. Hanley
Institutions: Children's National, George Washington University
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,500
OpenAlex ID: W2951049045